VC
CMPX icon

Vivo Capital’s Compass Therapeutics CMPX Stock Holding History

Vivo Capital’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17M Sell
7,757,060
-1,788,406
-19% -$5.28M 1.55% 25
2026
Q1 		$50.5M Hold
9,545,466
– – 4.2% 6
2025
Q4 		$51.3M Hold
9,545,466
– – 3.31% 7
2025
Q3 		$33.4M Buy
9,545,466
+3,502,000
+58% +$11.1M 2.69% 11
2025
Q2 		$15.7M Buy
6,043,466
+2,487,443
+70% +$5.13M 1.61% 11
2025
Q1 		$6.76M Hold
3,556,023
– – 0.89% 24
2024
Q4 		$5.16M Hold
3,556,023
– – 0.58% 33
2024
Q3 		$6.54M Hold
3,556,023
– – 0.54% 28
2024
Q2 		$3.56M Hold
3,556,023
– – 0.33% 32
2024
Q1 		$7.04M Hold
3,556,023
– – 0.55% 32
2023
Q4 		$5.55M Hold
3,556,023
– – 0.45% 34
2023
Q3 		$7.01M Hold
3,556,023
– – 0.77% 31
2023
Q2 		$11.3M Hold
3,556,023
– – 0.78% 22
2023
Q1 		$11.6M Sell
3,556,023
-1,607
-0% -$6.31K 0.81% 20
2022
Q4 		$17.9M Buy
3,557,630
+1,557,630
+78% +$6.21M 2.06% 17
2022
Q3 		$4.56M Hold
2,000,000
– – 0.5% 40
2022
Q2 		$5.3M Hold
2,000,000
– – 0.53% 35
2022
Q1 		$2.74M Hold
2,000,000
– – 0.19% 46
2021
Q4 		$6.34M Buy
+2,000,000
New +$6.63M 0.38% 43

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vivo Capital's CMPX Position: Q2 2026 in Review

Vivo Capital reduced its Compass Therapeutics (CMPX) stake by 19% in Q2 2026, selling an estimated $5.28M and leaving 7,757,060 shares worth $17M. The position accounts for 1.55% of the portfolio, ranked #25.

Vivo Capital first reported a position in CMPX in Q4 2021 and has held it in 19 quarters since. The position peaked at $51.3M in Q4 2025. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Vivo Capital held 7,757,060 shares of Compass Therapeutics worth $17M as of Q2 2026.
  • Vivo Capital sold 1,788,406 Compass Therapeutics shares in Q2 2026, an estimated $5.28M.
  • Compass Therapeutics made up 1.55% of Vivo Capital's portfolio in Q2 2026, its #25 holding.
  • Vivo Capital first reported a position in Compass Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • Vivo Capital's Compass Therapeutics position peaked at $51.3M in Q4 2025.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Vivo Capital's 13F filing for Q2 2026, filed 14 Aug 2026.